Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Meets the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) criteria for Systemic Lupus Erythematosus (SLE)~* Renal biopsy confirming a histologic diagnosis of active Lupus Nephritis (LN) International Scociety of Nephrology/Renal Pathology Society (ISN/RPS) Classes III, IV-S, or IV-G; or Class V~* Urine protein:creatinine ratio (UPCR) ≥1.5 mg/mg or UPCR ≥1 mg/mg assessed with a 24-hour urine specimen~Exclusion Criteria:~* Pure ISN/RPS Class V membranous LN~* Screening estimated glomerular filtration rate ≤30 mL/min/1.73 m\^2~* Dialysis within 12 months before screening or plans for dialysis within 6 months after enrollment in the study~* End-stage renal disease~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BMS-986165 Dose 1 (Type: EXPERIMENTAL): Specified Dose on Specified Days
- BMS-986165 Dose 2 (Type: EXPERIMENTAL): Specified Dose on Specified Days
- Placebo for BMS-986165 (Type: PLACEBO_COMPARATOR): Specified Dose on Specified Days
- Mycophenolate Mofetil (MMF) (Type: EXPERIMENTAL): Specified Dose on Specified Days

Based on this trial design, predict the completion outcome and termination type (if applicable).